Literature DB >> 23649001

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.

Mark Ibberson1, Sylvian Bron, Nicolas Guex, Eveline Faes-van't Hull, Assia Ifticene-Treboux, Luc Henry, Hans-Anton Lehr, Jean-François Delaloye, George Coukos, Ioannis Xenarios, Marie-Agnès Doucey.   

Abstract

PURPOSE: Tumor-associated TIE-2-expressing monocytes (TEM) are highly proangiogenic cells critical for tumor vascularization. We previously showed that, in human breast cancer, TIE-2 and VEGFR pathways control proangiogenic activity of TEMs. Here, we examine the contribution of these pathways to immunosuppressive activity of TEMs. EXPERIMENTAL
DESIGN: We investigated the changes in immunosuppressive activity of TEMs and gene expression in response to specific kinase inhibitors of TIE-2 and VEGFR. The ability of tumor TEMs to suppress tumor-specific T-cell response mediated by tumor dendritic cells (DC) was measured in vitro. Characterization of TEM and DC phenotype in addition to their interaction with T cells was done using confocal microscopic images analysis of breast carcinomas.
RESULTS: TEMs from breast tumors are able to suppress tumor-specific immune responses. Importantly, proangiogenic and suppressive functions of TEMs are similarly driven by TIE-2 and VEGFR kinase activity. Furthermore, we show that tumor TEMs can function as antigen-presenting cells and elicit a weak proliferation of T cells. Blocking TIE-2 and VEGFR kinase activity induced TEMs to change their phenotype into cells with features of myeloid dendritic cells. We show that immunosuppressive activity of TEMs is associated with high CD86 surface expression and extensive engagement of T regulatory cells in breast tumors. TIE-2 and VEGFR kinase activity was also necessary to maintain high CD86 surface expression levels and to convert T cells into regulatory cells.
CONCLUSIONS: These results suggest that TEMs are plastic cells that can be reverted from suppressive, proangiogenic cells into cells that are able to mediate an antitumoral immune response. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649001     DOI: 10.1158/1078-0432.CCR-12-3181

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response.

Authors:  Dominic Schauer; Patrick Starlinger; Lejla Alidzanovic; Philipp Zajc; Thomas Maier; Alexandra Feldman; Robin Padickakudy; Elisabeth Buchberger; Vanessa Elleder; Andreas Spittler; Judith Stift; Lorand Pop; Birgit Gruenberger; Thomas Gruenberger; Christine Brostjan
Journal:  Oncoimmunology       Date:  2016-03-22       Impact factor: 8.110

2.  Endosomal toll-like receptors play a key role in activation of primary human monocytes by cowpea mosaic virus.

Authors:  Marwah M Albakri; Frank A Veliz; Steven N Fiering; Nicole F Steinmetz; Scott F Sieg
Journal:  Immunology       Date:  2019-11-15       Impact factor: 7.397

3.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

4.  Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful.

Authors:  Izabela Szulc-Kielbik; Michal Kielbik
Journal:  Exp Suppl       Date:  2022

Review 5.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 6.  Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.

Authors:  Anita K Mehta; Sapana Kadel; Madeline G Townsend; Madisson Oliwa; Jennifer L Guerriero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

7.  Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.

Authors:  Florence T H Wu; Shan Man; Ping Xu; Annabelle Chow; Marta Paez-Ribes; Christina R Lee; Steven R Pirie-Shepherd; Urban Emmenegger; Robert S Kerbel
Journal:  Cancer Res       Date:  2016-09-20       Impact factor: 12.701

Review 8.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

9.  Toward a rational design of combination therapy in cancer.

Authors:  Marie-Agnès Doucey; Ioannis Xenarios
Journal:  Oncoimmunology       Date:  2015-07-07       Impact factor: 8.110

10.  Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression.

Authors:  Giulia Escobar; Bernhard Gentner; Luigi Naldini; Roberta Mazzieri
Journal:  Oncoimmunology       Date:  2014-04-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.